Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 7/20 | 0.60 |
| ▸ | GABBR1 | Q9UBS5 | 7/20 | 0.60 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 5/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.44 |
| ▸ | MERTK | Q12866 | 3/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115529 | 0.89 | GABBR2 (0.55) | GABBR2GABBR1TLR7AXLTYRO3 | |
| SCHEMBL3121498 | 0.87 | GABBR2 (0.67) | GABBR2GABBR1TLR7AXLTYRO3 | |
| SCHEMBL3118196 | 0.84 | GABBR2 (0.62) | GABBR2GABBR1TLR7AXLTYRO3 | |
| SCHEMBL3118159 | 0.83 | GABBR2 (0.68) | GABBR2GABBR1AXLTYRO3MERTK | |
| SCHEMBL3124036 | 0.79 | MERTK (0.47) | GABBR2GABBR1TLR7AXLTYRO3 | |
| SCHEMBL3113561 | 0.78 | GABBR2 (0.56) | GABBR2GABBR1TLR7AXLTYRO3 | |
| SCHEMBL13248661 | 0.76 | GABBR2 (0.72) | GABBR2GABBR1TLR7AXLTYRO3 | |
| SCHEMBL3121907 | 0.75 | GABBR2 (1.00) | GABBR2GABBR1AXLTYRO3MERTK | |
| Hydrochloric Acid SCHEMBL3119417 | 0.75 | GABBR2 (0.70) | GABBR2GABBR1TLR7AXLTYRO3 | |
| SCHEMBL3111419 | 0.74 | GABBR2 (1.00) | GABBR2GABBR1AXLTYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | GABBR2 1611/4885GABBR1 1499/4885TLR7 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.